期刊文献+

甘精胰岛素联合格列喹酮治疗糖尿病肾病的临床评价 被引量:3

Therapeutic Effect of Insulin Glargine Combined with Gliquidone for the Treatment of Patients with Diabetic Nephropathy
下载PDF
导出
摘要 目的观察糖尿病肾病患者采用甘精胰岛素联合格列喹酮治疗的临床效果及安全性。方法 58例糖尿病肾病患者随机分为对照组及治疗组,对照组采用胰岛素治疗,治疗组采用格列喹酮加甘精胰岛素联合治疗,比较两组患者治疗效果、肾功能及低血糖发生率。结果两组患者治疗后FBG、2hBG、HbA1c、UAER水平均降低,对照组与治疗组间无显著差异。两组患者治疗前BUN、SCr水平无明显变化。治疗组低血糖发生率低于对照组。结论甘精胰岛素联合格列喹酮治疗糖尿病肾病可有效控制血糖,安全性和依从性较单独使用胰岛素治疗好。 Objective To observe the efficacy and safety of insulin glargine combined with Gliquidone in patients with diabetic nephropathy. Methods Fifty eight patients with diabetic nephropathy were randomly divided into control group and treatment group; Patients in the treatment groups were treated by insulin glargine injection combined with Gliquidone and patients in the control group were treated by premixed insulin injection twice daily. Therapeutic efficacy, renal function and incidence of hypoglycemia were contrasted. Results After treatment, the levels of FBG, 2hBG, HbAlc and UAER in two groups all decreased obviously, but there were no statistically significant differences between the two groups. The levels of BUN, SCr had no marked difference after the experiment. Patients in the treatment group had fewer hypoglycemic episodes than those in the control group. Conclusion Insulin glargine combined with Gliquidone can control the blood glucose effectively in patients with diabetic nephropatby and has high safety accompanied by a simple and easy way in application.
出处 《中国现代医生》 2011年第17期68-69,共2页 China Modern Doctor
关键词 胰岛素 降血糖药 糖尿病肾病 Insulin Hypoglycemic agent Diabetic nephropathy
  • 相关文献

参考文献5

  • 1王战建,刘珊.糖尿病肾病发病机制的研究进展[J].国际泌尿系统杂志,2006,26(5):693-696. 被引量:41
  • 2Koyuturk M, Ozsoy-Sacan O, Bolkent S, et al. Effect of glurenorm on immunohistoehemical changes in pancreatic beta cells of rats in experimental diabetes[J]. Indian J Exp Biol,2005,43 ( 3 ) : 268-271.
  • 3刘国良,赵晓娟,都建,王秋月,张静,郑晓敏,曹翠平,任路平.糖适平治疗2型糖尿病的临床疗效观察[J].辽宁实用糖尿病杂志,2004,12(3):58-60. 被引量:10
  • 4Krzyzanowska-Swiniarska B, Czekalski S, Fuchs H, et al. Gliquidone-- opinions from the international literature[J]. Pol Tyg Lek, 1993,48 Suppl 1: 40-41.
  • 5Owens DR, Zinman B, Bolli GB. Insulins today and beyond[J]. Lancet,2001, 358 ( 9283 ) : 739-746.

二级参考文献15

  • 1李秀钧,金星,李美莲,于国宁,刘颖耿,刘永志,张喆,许樟荣,刘雪萍,冯登尧,冯颖,邓尚平,J.Limmer,池芝盛.糖适平治疗271例NIDDM的临床评价[J].中华内分泌代谢杂志,1993,9(1):8-11. 被引量:11
  • 2[2]Hani E H, Boutin P, Durand E, et al. Missence mutation in the pancreatic istet beta cell nwardly rectifying k channal gene (kir6.2) [J]. Diabetologis 1998 ;41:1511 - 1515.
  • 3[3]Turner RC. Millins H, Neil HAM, et al. Risk factors for cororary artery disease in non - insulin - dependent diabetes mellitusi United kindom Prospective Diabetes sutyd BMJ 1998;316:823 - 828.
  • 4[4]Kopitar z Koss FW. Pharmacokinefic behaviour of ARDF 26 a new sulphomy lurea Proceedings of the International Conference on glurenorm 1975; 25:1973.
  • 5Tsilibary EC.Microvascular basement membranes in diabetes mellitus.J Patho1,2003,200(4):537 -46.
  • 6Jensen LJ,Ostergard J,Flyvbjerg A.AGE-RAGE and AGE Cross -link interaction:important players in the pathogenesis of diabetic kidney disease.Horm Metab Res,2005,37 suppl 1:26 -34.
  • 7Wautier JL,Schmidt AM.Protein glycation:a firm link to endothelial cell dysfunction.Circ Res,2004,95 (3):233-8.
  • 8Banerjec S,Ghosh US,Saha SJ.Role of GFR estimation in assessment of the status of nephropathy in type 2 diabetes mellitus.J Assoc Physicians India,2005,53:181-4.
  • 9Jin Y,Moriya T,Tanaka K,et al.Glumerular hyperfiltration in no -proteinuric and non-hypertensive Janpanese type 2 diabetic patients Diabetes Rrs Clin Pract,2005:23.
  • 10Schena FP,Gesualdo L.Pathogenetic mechanisms of diabetic nephropathy.J AM Soc Nephrol.2005 , 16 Suppl 1:S30 -3.

共引文献49

同被引文献34

  • 1何敏,徐济良,吴锋.2型糖尿病大鼠主动脉内皮细胞氧化损伤及缬沙坦的保护作用[J].中国药理学通报,2007,23(3):354-358. 被引量:16
  • 2Sartorius N,Cimino L. The co-occurrence of diabetes and depression: an example of the worldwide epidemic of co- morbidity of mental and physical illness[J]. Ann Acad Med Singapore, 2012,41 (10) :430-431.
  • 3Gundtoft PH,Kristensen AK, Gulaksen BA,et al. Preva- lence of diabetes mellitus in patients with shoulder symp- toms is low[J]. Dan Med J,2013,60(10):A4705.
  • 4Petersen AB,Knop FK,Christensen M. Lixisenatide for the treatment of type 2 diabetes[J]. Drugs Today (Barc), 2013,49(9):537-553.
  • 5Canivell S, Ruano EG, Sise-Almirall A, et al. Gastric in- hibitory polypeptide receptor methylation in newly diag- nosed, drug-na ve patients with type 2diabetes: A case- control study[J]. PLoS One, 2013,8 (9): 75474.
  • 6Gao D,Ning N,Wang C,et al. Dairy products consump- tion and risk of type 2 diabetes: systematic review and dose-response meta-analysis[J]. PLoS One, 2013,8 (9): 73965.
  • 7Ajala O,English P,Pinkney J. Systematic review and meta- analysis of different dietary approaches to the management of type 2 diabetes[J]. Am J Clin Nutr,2013,97(3):505- 516.
  • 8Unnikrishnan AG,Bhattacharyya A,Baruah MP,et al. Impor- tance of achieving the composite endpoints in diabetes[J]. Indian J Endocrinol Metab,2013,17(5):835-843.
  • 9Khavandi K,Amer H,Ibrahim B,et al. Strategies for pre- venting type 2 diabetes: an update for clinicians[J]. Ther Adv Chronic Dis,2013,4(5):242-261.
  • 10Goto A,Goto M,Noda M,et al. Incidence of type 2 dia- betes in Japan: A systematic review and meta-analysis[J]. PLoS One,2013,8(9): 74699.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部